AnaCardio: Funding, Investors & Team (Oct 2026)
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio has raised $70.8M across 1 funding round on record, the most recent a Series B of $70.8M announced in Sep 2026.
That round is above the $4.5M median round size for Sweden companies tracked on FundedIQ over the last two years.
AnaCardio Company Profile and Key Stats
Latest funding round on record: Sep 2026.
AnaCardio Funding Rounds
AnaCardio Investors
14 investors are recorded in total; the 5 named above are those the record identifies.
AnaCardio Founders and Leadership Team
Contact details for the AnaCardio team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →AnaCardio Funding in Context
AnaCardio's latest round of $70.8M is above the median round in Sweden. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AnaCardio in Biopharma and Solna
Companies Similar to AnaCardio
At IPercept, we offer software solutions and services that utilize artificial intelligence and hardware to…
AI sales assistant that eliminates administrative work for revenue teams
Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every…
We make wireless hardware that offers best-in-class performance, size and weight.
Freya Industries is a security and defence technology company
Tandem Health is focused on delivering healthcare services, while Tandem enables users to easily document…
Tavion is a developer of battery energy storage systems that is expediting Europe's shift to renewable energy.
Greening the grid with second life batteries
Fluencify is an all in one software platform that automates, reviews, and runs high volume creator marketing…
Solace Care is a platform that prioritizes artificial intelligence to revolutionize the insurance sector by…
eComID provides AI-powered personalization and shopping technology for fashion brands.
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
AnaCardio Funding FAQs
What does AnaCardio do?
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
How much funding has AnaCardio raised?
AnaCardio has raised $70.8M across 1 round on record. The most recent is a Series B of $70.8M announced in Sep 2026.
When did AnaCardio last raise funding?
AnaCardio's most recent funding round on record is a Series B of $70.8M, announced in Sep 2026.
Who has invested in AnaCardio?
Investors on record for AnaCardio include Innovestor, Novo Holdings, Sound Bioventures, Pureos Bioventures, Industrifonden. FundedIQ records 14 investors in total.
Where is AnaCardio headquartered?
AnaCardio is based in Solna, Sweden.
How many employees does AnaCardio have?
AnaCardio is in the 11-50 employee band.
When was AnaCardio founded?
AnaCardio was founded in 2017.
About FundedIQ's AnaCardio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AnaCardio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.